AAAAAA

   
Results: 1-15 |
Results: 15
Increased incidence of indinavir nephrolithiasis in patients with hepatitis B or C virus infection
Authors: Malavaud, B Dinh, B Bonnet, E Izopet, J Payen, JL Marchou, B
Citation: B. Malavaud et al., Increased incidence of indinavir nephrolithiasis in patients with hepatitis B or C virus infection, ANTIVIR TH, 5(1), 2000, pp. 3-5
Transjugular intrahepatic portosystemic shunts in the treatment of refractory ascites: Results in 48 consecutive patients
Authors: Peron, JM Barange, K Otal, P Rousseau, H Payen, JL Pascal, JP Joffre, F Vinel, JP
Citation: Jm. Peron et al., Transjugular intrahepatic portosystemic shunts in the treatment of refractory ascites: Results in 48 consecutive patients, J VAS INT R, 11(9), 2000, pp. 1211-1216
Transmissions of hepatitis C virus during the ancillary procedures for assisted conception
Authors: Lesourd, F Izopet, J Mervan, C Payen, JL Sandres, K Monrozies, X Parinaud, J
Citation: F. Lesourd et al., Transmissions of hepatitis C virus during the ancillary procedures for assisted conception, HUM REPR, 15(5), 2000, pp. 1083-1085
Does HIV-infection influence the response of chronic hepatitis C to interferon treatment? A French multicenter prospective study
Authors: Causse, X Payen, JL Izopet, J Babany, G Girardin, MFS
Citation: X. Causse et al., Does HIV-infection influence the response of chronic hepatitis C to interferon treatment? A French multicenter prospective study, J HEPATOL, 32(6), 2000, pp. 1003-1010
Genetic heterogeneity of hypervariable region 1 of the hepatitis C virus (HCV) genome and sensitivity of HCV to alpha interferon therapy
Authors: Sandres, K Dubois, M Pasquier, C Payen, JL Alric, L Duffaut, M Vinel, JP Pascal, JP Puel, J Izopet, J
Citation: K. Sandres et al., Genetic heterogeneity of hypervariable region 1 of the hepatitis C virus (HCV) genome and sensitivity of HCV to alpha interferon therapy, J VIROLOGY, 74(2), 2000, pp. 661-668
A strange resident in the colon
Authors: Payen, JL Hervieu, C Couret, B Pascal, JP
Citation: Jl. Payen et al., A strange resident in the colon, ENDOSCOPY, 32(8), 2000, pp. S51-S51
Lack of effect of propranolol in the prevention of large oesophageal varices in patients with cirrhosis: a randomized trial
Authors: Cales, P Oberti, F Payen, JL Naveau, S Guyader, D Blanc, P Abergel, A Bichard, P Raymond, JM Canva-Delcambre, V Vetter, D Valla, D Beauchant, M Hadengue, A Champigneulle, B Pascal, JP Poynard, T Lebrec, D
Citation: P. Cales et al., Lack of effect of propranolol in the prevention of large oesophageal varices in patients with cirrhosis: a randomized trial, EUR J GASTR, 11(7), 1999, pp. 741-745
Treatment of refractory hydrothorax in cirrhosis with transjugular intrahepatic porto-systemic shunt
Authors: Peron, JM Dupuis, E Alric, L Ottal, P Rousseau, H Barange, K Payen, JL Pascal, JP Vinel, JP
Citation: Jm. Peron et al., Treatment of refractory hydrothorax in cirrhosis with transjugular intrahepatic porto-systemic shunt, GASTRO CL B, 23(3), 1999, pp. 414-415
A pharmacokinetic model for alpha interferon administered subcutaneously
Authors: Chatelut, E Rostaing, L Gregoire, N Payen, JL Pujol, A Izopet, J Houin, G Canal, P
Citation: E. Chatelut et al., A pharmacokinetic model for alpha interferon administered subcutaneously, BR J CL PH, 47(4), 1999, pp. 365-371
Transjugular intrahepatic portosystemic shunt in the treatment of refractory bleeding from ruptured gastric varices
Authors: Barange, K Peron, JM Imani, K Otal, P Payen, JL Rousseau, H Pascal, JP Joffre, F Vinel, JP
Citation: K. Barange et al., Transjugular intrahepatic portosystemic shunt in the treatment of refractory bleeding from ruptured gastric varices, HEPATOLOGY, 30(5), 1999, pp. 1139-1143
Treatment of hepatitis c virus-related cirrhosis: A randomized, controlledtrial of interferon alfa-2b versus no treatment
Authors: Valla, DC Chevallier, M Marcellin, P Payen, JL Trepo, C Fonck, M Bourliere, M Boucher, E Miguet, JP Parlier, D Lemonnier, C Opolon, P
Citation: Dc. Valla et al., Treatment of hepatitis c virus-related cirrhosis: A randomized, controlledtrial of interferon alfa-2b versus no treatment, HEPATOLOGY, 29(6), 1999, pp. 1870-1875
Prostate-specific antigen in acute hepatitis and hepatocellular carcinoma
Authors: Malavaud, B Miedouge, M Payen, JL Izopet, J Rischmann, P Pascal, JP Sarramon, JP Serre, G
Citation: B. Malavaud et al., Prostate-specific antigen in acute hepatitis and hepatocellular carcinoma, PROSTATE, 41(4), 1999, pp. 258-262
Study of the association between major histocompatibility complex class IIgenes and the response to interferon alpha in patients with chronic hepatitis C infection
Authors: Alric, L Izopet, J Fort, M Vinel, JP Fontenelle, P Orfila, C Payen, JL Sandres, K Desmorat, H Charlet, JP Duffaut, M Abbal, M
Citation: L. Alric et al., Study of the association between major histocompatibility complex class IIgenes and the response to interferon alpha in patients with chronic hepatitis C infection, HUMAN IMMUN, 60(6), 1999, pp. 516-523
Cardiac toxicity and immunomodulators: a case report
Authors: Bousquet, E Amar, J Payen, JL Salvador, M Chamontin, B
Citation: E. Bousquet et al., Cardiac toxicity and immunomodulators: a case report, THERAPIE, 54(4), 1999, pp. 496-498
Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: A multicenter,controlled, randomized trial
Authors: Payen, JL Izopet, J Galindo-Migeot, V Lauwers-Cances, V Zarski, JP Seigneurin, JM Dussaix, E Voigt, JJ Selves, J Barange, K Puel, J Pascal, JP
Citation: Jl. Payen et al., Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: A multicenter,controlled, randomized trial, HEPATOLOGY, 28(6), 1998, pp. 1680-1686
Risultati: 1-15 |